Skip to content
Back to meeting Original
A pancreatic cancer doctor· @DanZhaoMD · X·· 1 day agoScore45
Body

KRASi is moving into neoadjuvant treatment of pancreatic cancer and showed promising results in different combinations: #ESMO26 KRAS G12Di inhibitor HRS-4642 combined with chemo, IO, or anti-EGFR trials in China. More options for pancreatic patients are coming.

21 views · 0 likes · 0 reposts · 0 replies

Source: A pancreatic cancer doctor · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.